@kayothera.bsky.social
Reposted
"The risky path might not be as risky as you thought compared to your other options..." Interview of Nick Ouzounov *15, MolBio grad alum and co-founder of Geltor, makers of biodesigned proteins and polypeptides. Leading-up to Many Minds, Many Stripes conference molbio.princeton.edu/news/2025/ni...
Nick Ouzounov *15, Cofounder of Geltor
Molbio alumnus Nick Ouzounov *15 is a co-founder with Alex Lorestani *17 of Geltor, makers of biodesigned proteins and polypeptides for beauty, wellness, and beyond. In this exclusive interview by Mol...
molbio.princeton.edu
May 22, 2025 at 9:01 PM
"The risky path might not be as risky as you thought compared to your other options..." Interview of Nick Ouzounov *15, MolBio grad alum and co-founder of Geltor, makers of biodesigned proteins and polypeptides. Leading-up to Many Minds, Many Stripes conference molbio.princeton.edu/news/2025/ni...
Reposted
#IRA’s small molecule penalty disproportionately harms early-stage drug development and has far greater harmful impact on innovation & patients than previously recognized. #CBO should incorporate real-world insights from specialist investors into its models.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
The Impact of the Inflation Reduction Act on Investment in Innovative Medicines: A Project-Level Analysis - Therapeutic Innovation & Regulatory Science
The impact of Medicare’s price negotiation on long-term pharmaceutical innovation and patient welfare remains one of the most widely debated topics across stakeholder groups. Existing policy simulatio...
link.springer.com
April 3, 2025 at 4:52 PM
#IRA’s small molecule penalty disproportionately harms early-stage drug development and has far greater harmful impact on innovation & patients than previously recognized. #CBO should incorporate real-world insights from specialist investors into its models.
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Reposted
"Do things well, don’t be afraid to ask–people want to help!" says Kevin Forrest *05, MolBio grad alum and co-founder of Kate Therapeutics, a biotech startup recently acquired by Novartis. Leading up to Princeton Alumni Many Minds, Many Stripes conference. molbio.princeton.edu/news/2025/ke...
Kevin Forrest *05, Biotech Executive and Cofounder of Kate Therapeutics
Kevin Forrest *05 is the co-founder of Kate Therapeutics; a biotech startup that recently made waves by being acquired by Novartis. In this exclusive interview by Molecular Biology Graduate Student De...
molbio.princeton.edu
April 11, 2025 at 4:12 PM
"Do things well, don’t be afraid to ask–people want to help!" says Kevin Forrest *05, MolBio grad alum and co-founder of Kate Therapeutics, a biotech startup recently acquired by Novartis. Leading up to Princeton Alumni Many Minds, Many Stripes conference. molbio.princeton.edu/news/2025/ke...